

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 26, 2016**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Tobira Therapeutics, Inc.

File No. 001-35953 - CF#33848

Tobira Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on May 9, 2016, as amended on September 9, 2016.

Based on representations by Tobira Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

| | |
|--------------|------------------------|
| Exhibit 10.1 | through April 11, 2026 |
| Exhibit 10.2 | through April 11, 2026 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary